Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have
shown that those taking donepezil have a lower rate of bone fractures, but the reasons for
this are unknown. The purpose of this study is to measure the effect of donepezil treatment
on bone metabolism factors including bone mineral density, bone turnover markers, and bone
quality.
Participants in this study will have a bone density test and have blood samples collected at
the baseline study visit. Participants will then be randomly assigned to donepezil or
matching placebo to be taken daily by mouth for 12 months. Blood samples will be collected at
6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will
also complete questionnaires at each study visit.